FDA fast tracks SAR402663 intravitreal gene therapy for wet AMD

Key takeaways:

SAR402663 is a one-time intravitreal gene therapy designed to reduce treatment burden.

It is currently being investigated in a phase 1/2 trial.

Editor’s note: This is a developing news story. Please check back soon for updates.

The FDA granted fast track designation to SAR402663, an intravitreal gene therapy for the treatment of wet age-related macular degeneration , according to a press release from Sanofi.

SAR402663 is currently being investigated in a phase 1/2 trial.

The gene therapy is designed to inhibit abnormal blood vessel growth, reduce vascular leakage and minimize retina damage by delivering genetic material encoding soluble FLT01 to inhibit VEGF in patients with wet AMD. It is a one-time intravitreal therapy aimed at eliminating the burden of frequent in